Alvotech (ALVO) Could Be 14% Undervalued On Manufacturing Capacity Updates

Alvotech (NasdaqGM:ALVO) is back in focus after two closely timed manufacturing updates that reshape how its biosimilars could be supplied to major markets. Both moves revolve around capacity, regulatory readiness, and long term supply security. Recent trading shows that Alvotech has been back on investors’ radar, with a 30-day share price return of 9.96% and a 90-day move of 76.20% pointing to building momentum around the manufacturing updates, even though the 1-year total shareholder return...